Lantheus Holdings, Inc. (LNTH) Stock Analysis
Temp Headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $85.58, A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: PYLARIFY; Concentration risk — Supplier: Jubilant HollisterStier.
Lantheus is a radiopharmaceutical company with PYLARIFY (PSMA PET for prostate cancer), DEFINITY (echocardiography contrast agent, >80% U.S. market share), and Neuraceq (amyloid PET for Alzheimer's). Products sold primarily to hospitals and imaging centers in the U.S. through a... Read more
Sell if holding. At $85.58, A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: PYLARIFY; Concentration risk — Supplier: Jubilant HollisterStier. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPYLARIFY10-K Item 1A: 'Continued substantial revenue contribution from PYLARIFY is dependent on (A) the ability of positron emission tomography ("PET") manufacturing facilities ("PMFs") to manufacture PYLARIFY'
- HIGHSupplierJubilant HollisterStier10-K Item 1A: 'We rely on Jubilant HollisterStier as a substantial supplier of DEFINITY.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $85.58, A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: PYLARIFY; Concentration risk — Supplier: Jubilant HollisterStier. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $80.95. Score 5.6/10, moderate confidence.
Take-profit target: $84.08 (-1.8% upside). Prior stop was $80.95. Stop-loss: $80.95.
Concentration risk — Product: PYLARIFY; Concentration risk — Supplier: Jubilant HollisterStier; Analyst target reached - limited upside remaining.
Lantheus Holdings, Inc. trades at a P/E of 24.8 (forward 13.4). TrendMatrix value score: 6.6/10. Verdict: Sell.
19 analysts cover LNTH with a consensus score of 4.1/5. Average price target: $95.
What does Lantheus Holdings, Inc. do?Lantheus is a radiopharmaceutical company with PYLARIFY (PSMA PET for prostate cancer), DEFINITY (echocardiography...
Lantheus is a radiopharmaceutical company with PYLARIFY (PSMA PET for prostate cancer), DEFINITY (echocardiography contrast agent, >80% U.S. market share), and Neuraceq (amyloid PET for Alzheimer's). Products sold primarily to hospitals and imaging centers in the U.S. through a PMF manufacturing network.